Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi Sells 3,111 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,111 shares of the firm’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $3.52, for a total value of $10,950.72. Following the sale, the chief technology officer now directly owns 1,753,370 shares in the company, valued at approximately $6,171,862.40. This trade represents a 0.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Sight Sciences Stock Performance

Shares of SGHT stock opened at $3.40 on Tuesday. The stock has a market capitalization of $172.57 million, a PE ratio of -3.33 and a beta of 2.57. The business’s 50 day simple moving average is $3.97 and its 200 day simple moving average is $5.60. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. Sight Sciences, Inc. has a one year low of $3.30 and a one year high of $8.45.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The firm had revenue of $20.16 million for the quarter, compared to the consensus estimate of $20.41 million. As a group, research analysts forecast that Sight Sciences, Inc. will post -1.01 earnings per share for the current year.

Analyst Ratings Changes

SGHT has been the subject of several research reports. Lake Street Capital downgraded Sight Sciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $10.00 to $5.00 in a research report on Monday, November 4th. Morgan Stanley dropped their price objective on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, November 11th. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a report on Friday, November 8th. UBS Group started coverage on shares of Sight Sciences in a research report on Friday, December 6th. They issued a “buy” rating and a $5.50 price target for the company. Finally, Piper Sandler reiterated a “neutral” rating and set a $5.50 price target (down previously from $6.00) on shares of Sight Sciences in a report on Friday, November 8th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Sight Sciences currently has a consensus rating of “Hold” and a consensus target price of $5.12.

Institutional Trading of Sight Sciences

A number of institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in shares of Sight Sciences by 335.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 69,660 shares of the company’s stock worth $439,000 after acquiring an additional 53,658 shares in the last quarter. B. Riley Wealth Advisors Inc. boosted its position in shares of Sight Sciences by 5.4% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock valued at $1,174,000 after purchasing an additional 10,000 shares in the last quarter. Barclays PLC grew its stake in Sight Sciences by 317.4% during the third quarter. Barclays PLC now owns 50,300 shares of the company’s stock worth $317,000 after purchasing an additional 38,248 shares during the period. Geode Capital Management LLC increased its holdings in Sight Sciences by 1.6% in the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after purchasing an additional 12,709 shares in the last quarter. Finally, State Street Corp lifted its stake in Sight Sciences by 17.4% in the third quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after buying an additional 95,843 shares during the period. Institutional investors own 55.51% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.